BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Rockland Immunochemicals Develops Cell Signaling Antibodies Through Unique Partnership


4/2/2012 9:37:26 AM

Gilbertsville, PA. April 2, 2012 – Rockland Immunochemicals Inc., a biotechnology company focusing on antibodies and antibody-based tools for basic research, diagnostic assay development and preclinical studies announced the release of 95 antibodies that are involved in signal transduction and cancer research. The antibodies were developed through a partnership with the National Cancer Institute’s Center for Cancer Research. The goal of this collaboration is to combine basic and applied research by working with life science researchers to develop better bioreagents that will facilitate biomedical research.

“Rockland’s antibody technology platform continues to be widely received by the research and biopharma community,” commented James Fendrick, CEO of Rockland Immunochemicals. “We anticipate continued success in our antibody efforts with NCI to discover and develop both novel and existing antibody targets that have broad application in the life science markets.”

All of the antibodies made under the NCI Rockland collaboration are produced in Rockland laboratories located west of Philadelphia, PA. It is anticipated that these reagents will assist in the understanding cell function and disease.

About Rockland Immunochemicals

Rockland Immunochemicals has supported the research, BioPharma and diagnostic industries for over 50 years with the highest quality antibodies and antibody based tools. Rockland is engaged in the development of new technologies for the production of antibodies for western blotting, immunohistochemistry (IHC), immunofluorescence microscopy, ELISA and FLOW cytometry. More information about Rockland Immunochemicals and its products and services can be found at the company's web site at www.rockland-inc.com

For additional information regarding this announcement, please contact:

Tabitha Patrick

Communications, Rockland Immunochemicals Inc.

Phone: 610.369.1008

Email: patrick@rockland-inc.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES